This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
by Zacks Equity Research
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
NVONegative Net Change FOLDPositive Net Change AVDLNo Net Change SKYEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
GSKNegative Net Change MRKPositive Net Change GILDPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance
by Zacks Equity Research
Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and niche leasing strength.
AMZNPositive Net Change MSFTPositive Net Change JNJNegative Net Change WLFCPositive Net Change
computers pharmaceuticals retail transportation
The Zacks Analyst Blog Highlights Delta Airlines, Levi Strauss, Pfizer, Zoom Communications , Fresnillo and Kyocera
by Zacks Equity Research
Zacks Analyst Blog features Delta Airlines, Levi Strauss, Pfizer, Zoom Communications, Fresnillo, and Kyocera as markets hit record highs despite a U.S. government shutdown.
PFEPositive Net Change DALPositive Net Change FNLPFNegative Net Change KYOCYPositive Net Change LEVINegative Net Change ZMPositive Net Change
computers pharmaceuticals precious-metals retail transportation
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
PFEPositive Net Change MRKPositive Net Change SMMTPositive Net Change
pharmaceuticals
Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson
by Mark Vickery
Microsoft rides AI and cloud growth, Amazon leans on AWS and Prime, and Johnson & Johnson gains from strong pharma momentum despite patent risks.
AMZNPositive Net Change GDPositive Net Change MSFTPositive Net Change JNJNegative Net Change AEMNegative Net Change KMINegative Net Change WLFCPositive Net Change
computers pharmaceuticals retail transportation
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
by Zacks Equity Research
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
AZNNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
RHHBYNegative Net Change JAZZPositive Net Change ETNBNegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
by Sundeep Ganoria
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
AZNNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
by Zacks Equity Research
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
CRMDNegative Net Change MRUSPositive Net Change KNSAPositive Net Change GMABPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk
by Zacks Equity Research
Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.
PFEPositive Net Change NVONegative Net Change MRKPositive Net Change LLYPositive Net Change ABBVNegative Net Change
medical pharmaceuticals
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
by Kinjel Shah
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
AZNNegative Net Change JNJNegative Net Change AMGNNegative Net Change ABBVNegative Net Change
pharmaceuticals
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
by Santanu Roy
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
GSPositive Net Change JNJNegative Net Change HSYNegative Net Change HDPositive Net Change AZONegative Net Change VPGNegative Net Change LDOSNegative Net Change SHOPPositive Net Change NOBLPositive Net Change NTLANegative Net Change AMRXPositive Net Change HIPOPositive Net Change
computers consumer-staples finance insurance medical pharmaceuticals retail
4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio
by Sanghamitra Saha
Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.
PFEPositive Net Change PJPPositive Net Change IHEPositive Net Change XPHPositive Net Change PPHPositive Net Change
etfs pharmaceuticals
5 Large Cap Drug Stocks: Values or Traps?
by Tracey Ryniec
Some drug stocks are cheap but is it another fake out?
PFEPositive Net Change NVONegative Net Change MRKPositive Net Change LLYPositive Net Change ABBVNegative Net Change
pharmaceuticals
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
by Kanishka Das
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
by Kinjel Shah
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
AZNNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
pharmaceuticals
Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
by Ahan Chakraborty
NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.
BMYNo Net Change NVONegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
by Sundeep Ganoria
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
by Zacks Equity Research
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
BMYNo Net Change BAYRYPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
ALNYNegative Net Change NVSNegative Net Change PFEPositive Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
by Zacks Equity Research
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
SNYPositive Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Oct 1, 2025
by Zacks Equity Research
Companies in The News Are: LW, UNFI, PRGS, ABBV
UNFINegative Net Change PRGSPositive Net Change ABBVNegative Net Change LWPositive Net Change
consumer-staples pharmaceuticals
Stock Market News for Oct 1, 2025
by Zacks Equity Research
Wall Street closed higher on Tuesday, driven by healthcare stocks.
PFEPositive Net Change LLYPositive Net Change
pharmaceuticals